eCIO Initiates Stake in Eli Lilly and Company (LLY) with 886 Shares

Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During the first quarter, eCIO Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) through the purchase of 886 shares. According to the latest disclosure with the SEC, the firm’s investment in the company is valued at approximately $732,000.

At a time when being lean is the new luxury, Eli Lilly and Company (NYSE:LLY) is doing what it does best. The company is focusing on obesity and type 2 diabetes treatment markets at a speed only a few can match. While the tirzepatide franchise captures the GLP-1 market, the company’s orforglipron, an experimental drug, continues to be more effective than the competitor’s Rybelsus.

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

The comparative statistics are a testament to the company’s strong market standing, with its 3-year and 5-year returns surpassing the market’s returns by 78.37% and 332.72%, respectively. With confidence around the oral GLP-1 segment, entering a pivotal stage of growth in 2026 onwards, we can only expect Eli Lilly and Company (NYSE:LLY) to outperform.

Eli Lilly and Company (NYSE:LLY) is an Indiana-based company that specializes in human pharmaceuticals. Founded in 1876, the company is committed to making life better for people all over the globe.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.